Immuron Ltd — Capital/Financing Update 2015

Oct 25, 2015

==> picture [221 x 62] intentionally omitted <==

Immuron Executes US Travelan Sales Partnership with Passport Health, a US Leader in Travel Clinics

26 October 2015, Melbourne, Australia: Immuron Limited is pleased to announce that the Company has executed a partnership with US travel clinic leader Passport Health for the sale of Travelan throughout its clinic network. The specific terms and conditions of this agreement will remain confidential.

Passport Health is the largest provider of travel medicine and immunisation services in North America. With more than 250 travel clinic locations, a commitment to first class medical care, and rigorously trained medical staff, Passport Health has set a standard of excellence for patient care. Passport Health has leveraged its deep experience with travel medicine to service the vaccination, wellness, examination and records management needs of corporations, government agencies and other large organisations.

Passport Health was founded in 1994 by Fran Lessans. Each travel clinic serves its local community via convenient locations where the public can access travel medicine specialists who have received rigorous training in the fields of travel medicine and immunology.

The CEO and founder of Passport Health, Fran Lessans said;

“We are pleased to be able to offer our travelers a natural over-the-counter product that has been widely used in Australia for many years to reduce the risk of Traveler’s Diarrhea, the number 1 ailment encountered by travelers.”

Immuron CEO Mr. Liquard added;

“We are excited to have Travelan now available throughout Passport Health, via both their corporate and independent franchises. This is another major agreement for Travelan in the US for 2015, as we continue our efforts to grow the Travelan brand in the US through new distribution and retail partners.”

Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder, a rich source of antibodies that bind to Enterotoxigenic E. coli in the gastrointestinal tract, preventing them from attaching to the intestinal wall and thereby neutralising their ability to cause Travellers’ Diarrhoea and its associated symptoms. Hyperimmune Colostrum is developed under Immuron’s proprietary technology to be high in antibodies to a range of E- Coli bacteria that is present in normal colostrum in very small amounts.

Contact:

Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 Email: thomasliquard@immuron.com

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735